Biological
Relmacabtagene Autoleucel
Relmacabtagene Autoleucel is a biological therapy with 4 clinical trials. Currently 1 active trials ongoing.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
1(25%)
Phase Distribution
Ph phase_2
2
50%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Other(2)
Detailed Status
unknown2
Active, not recruiting1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 22 (100.0%)
Trials by Status
active_not_recruiting125%
not_yet_recruiting125%
unknown250%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruitingphase_2
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
NCT06093841
unknown
Relmacabtagene Autoleucel in Patients With LBCL
NCT06142175
unknownphase_2
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
NCT05590221
not_yet_recruiting
Relmacabtagene Autoleucel in Hematologic Malignancies
NCT06142188
Clinical Trials (4)
Showing 4 of 4 trials
NCT06093841Phase 2
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
NCT06142175
Relmacabtagene Autoleucel in Patients With LBCL
NCT05590221Phase 2
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
NCT06142188
Relmacabtagene Autoleucel in Hematologic Malignancies
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4